Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The glucagon receptor component in retatrutide likely drives the additional weight loss through increased energy expenditure and enhanced hepatic fat metabolism mechanisms not directly targeted by GLP-1 or GIP activation alone
Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese
Patients with a dual therapy with metformin and a DPP-4 inhibitor can also receive a further treatment intensification with a SGLT-2 inhibitor or a TZD (7074)
However, comprehensive data on the direct effects of HF are still being developed (NCT04847557)
US$ 23.09
US$ 28.27
US$ 24.92
US$ 24.40
US$ 29.73
